Close Menu
    Emirati StarEmirati Star
    • Automotive
    • Business
    • Entertainment
    • Health
    • Luxury
    • Lifestyle
    • News
    • Sports
    • Technology
    • Travel
    Emirati StarEmirati Star
    Home » Innovative experimental malaria drug based on antibodies discovered
    Featured News

    Innovative experimental malaria drug based on antibodies discovered

    November 1, 2022
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    A new study in Africa has found that a one-time dose of an experimental drug protects adults against malaria for at least six months. In 2020, malaria killed more than 620,000 people and sickened 241 million, mostly children under 5. There is a malaria vaccine being rolled out by the World Health Organization for children, but it is only 30% effective and requires four doses.

    Innovative experimental malaria drug based on antibodies discoveredIn this new study, people received a large dose of lab-made malaria-fighting antibodies instead of relying on the immune system to make enough of those same infection-blockers after vaccination, reported the Associated Press (AP). “There are not enough people protected by the vaccine available,” said Kassoum Kayentao, a researcher from the University of Sciences, Techniques and Technologies in Bamako, Mali.

    In those villages, people are bitten by infected mosquitoes on average twice a day during malaria season, according to other research. Experimental antibody, developed by researchers at the US National Institutes of Health, was delivered by IV. In the meantime, an easy-to-administer shot version from the same scientists is in early testing in infants, children, and adults.

    Research presented at a medical meeting in Seattle was published Monday in the New England Journal of Medicine. In order to work, the antibody breaks the life cycle of the parasite, which is spread through mosquito bites. It targets immature parasites before they mature and multiply in the liver. An antibody taken from a volunteer who received a malaria vaccine was used to develop it.

    It involved 330 adults in Mali who received either a dummy infusion or two different antibody doses. Every two weeks for 24 weeks, all were tested for malaria infection. Treatment was provided to anyone who became ill. A blood test detected infections in 20 people who received the higher dose, 39 people who received the lower dose, and 86 people who received the placebo. Compared to the placebo, the higher dose was 88% effective. There was a 75% effectiveness rate for the lower dose.

    During a malaria season, protection might last for several months. In the future, it could be used in conjunction with other malaria prevention methods, such as malaria pills, mosquito nets, and vaccinations. According to one estimate, lab-made antibodies could be given for as little as $5 per child per malaria season.

    Related Posts

    Network International and AdalFi Partner to Unlock Data-Driven Lending Across the Middle East and Africa

    November 16, 2026

    Narwal Unveils Flow 2: Revolutionary FlowWash Mopping System with VLM OmniVision Intelligence

    November 14, 2026

    IGNITE Launches MENA Platform in Dubai, Bringing Together Entrepreneurship, AI-Powered Learning and Global Consumer Brands

    October 12, 2026

    Chef Ayşenur Opens À La Molu at Dubai’s Azizi Riviera

    October 9, 2026

    Dataroid Recognized in the Gartner® Market Guide for Product Analytics (2026)

    October 6, 2026

    Inspira Enterprise Named Major Contender in Everest Group’s 2026 Cybersecurity Services PEAK Matrix®

    September 29, 2026
    Latest News

    Ebola cases top 11,200 as Africa CDC warns of record outbreak

    November 16, 2026

    Sheikh Mohamed and Ramos-Horta talk trade, energy and ASEAN

    November 16, 2026

    Yellow fever kills 18 across nine African nations, WHO says

    November 15, 2026

    Sheikh Mohamed receives Arab League chief Nabil Fahmy

    November 14, 2026

    AfDB backs Morocco reforms and climate resilience with €434.4m

    November 14, 2026

    Three nations launch carbon crediting initiative at COP31

    November 13, 2026

    DP World partner ATI wins 25-year Manila port renewal

    November 13, 2026

    Nigeria and EU seal readmission deal after decade of talks

    November 12, 2026
    © 2026 Emirati Star | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.